Compare RENT & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RENT | TNYA |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.3M | 178.5M |
| IPO Year | 2021 | 2021 |
| Metric | RENT | TNYA |
|---|---|---|
| Price | $4.60 | $1.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.33 |
| AVG Volume (30 Days) | 104.0K | ★ 3.5M |
| Earning Date | 04-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 110.16 | 54.96 |
| EPS | ★ 1.88 | N/A |
| Revenue | ★ $329,800,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.53 | ★ N/A |
| Revenue Growth | ★ 7.71 | N/A |
| 52 Week Low | $3.70 | $0.36 |
| 52 Week High | $10.13 | $2.35 |
| Indicator | RENT | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 41.35 | 72.04 |
| Support Level | $4.38 | $0.65 |
| Resistance Level | $4.92 | $1.04 |
| Average True Range (ATR) | 0.24 | 0.07 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 16.67 | 73.74 |
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe to, or buy designer apparel and accessories. The company gives customers access to its unlimited closet through its subscription offering (Subscription) or the ability to rent a-la-carte through its reserve offering (Reserve). The company also gives its subscribers and customers the ability to buy its products through its Resale offering. The Closet in the Cloud offers a wide assortment of items for every occasion, from evening wear and accessories to ready-to-wear, workwear, denim, casual, maternity, outerwear, blouses, knitwear, loungewear, jewelry, handbags, activewear, and ski wear.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.